Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
About
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Lorlatinib - PF-06463922

N/AApproved For MarketingNCT03127618

Pfizer

Overview

Lorlatinib expanded access program

Study Type

EXPANDED_ACCESS

Interventions

Eligibility

Min age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult, Senior Exclusion Criteria: \-

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT03127618 - Lorlatinib - PF-06463922 | Crick | Crick